WHO Regional Office for Europe advice on the use of experimental
medicines for the treatment of COVID-19 patients
9 April 2020
Contents
Background ................................................................................................................................................... 1
WHO recommendations for the treatment of COVID-19 patients ............................................................... 2
Use of experimental drugs for the management of COVID-19 patients ...................................................... 2
WHO Solidarity clinical trial on potential COVID-19 treatment options ...................................................... 3
Non-SOLIDARITY Trial potential treatments ................................................................................................. 3
WHO Research and Development Blueprint ................................................................................................ 4
Global availability of essential medicines ..................................................................................................... 5
Background
This advice was developed to address questions from Member States regarding the use of
experimental medicines in the treatment of COVID-19 patients. It summarizes current WHO
recommendations for the treatment of COVID-19 patients, information on the ethical and legal
requirements for the use of experimental medicines in clinical trials (the WHO SOLIDARITY
trial or other Randomized Control Trials (RCT)) as well as donated medicines, and the possible
impact on global supplies of essential medicines for the treatment of non-COIVD-19 patients
where these drugs are included in COVID-19 clinical trials.
1
WHO recommendations for the treatment of COVID-19 patients
WHO has published the guidance “Clinical management of severe acute respiratory infection
(SARI) when COVID-19 disease is suspected” This document is intended for clinicians taking
care of hospitalized adult and paediatric patients with severe acute respiratory infection (SARI)
when COVID-19 infection is suspected. Optimized supportive care should be provided to ensure
the best possible chance for survival of COVID-19 patients as described in the WHO guidance:
1. Management of severe COVID-19 requires oxygen therapy and monitoring.
Supplemental oxygen therapy should be given immediately to patients with SARI and
respiratory distress, hypoxaemia or shock.
2. Management of critical COVID-19 (acute respiratory distress syndrome (ARDS))
requires advanced oxygen/ventilatory support.
https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-
coronavirus-(ncov)-infection-is-suspected[1]
Use of experimental drugs for the management of COVID-19 patients
There are currently no known effective or licensed treatment options for COVID-19. The public
demand for identifying effective COVID-19 therapies to treat critically ill patients is leading
many countries to initiate multiple small studies and compassionate use of candidate therapeutics
of unknown or partially known effectiveness for treatment.
Globally randomized clinical trials are ongoing, including the WHO SOLIDARITY trial, but the
use of these medicines for management of COVID-19 remains experimental. It is therefore
critical that these medicines are provided under the safeguards of national regulations for clinical
trials. All the medicines included in SOLIDARITY have known safety profiles for other
conditions than COVID-19 and therefore may have significant side effects particularly when
combined with other drugs. Robust pharmacovigilance and adverse event reporting are
important. WHO teams are at your disposal to discuss the details.
[email protected]
If conducting a randomized controlled trial (RCT) is not possible, then the use of all
investigational therapeutics should be done under Monitored Emergency Use of Unregistered
Interventions Framework (MEURI). WHO has issued a scientific brief on the off-label use of
medicines for COVID-19. The paper stipulates that it can be ethically appropriate to offer
individual patients experimental interventions on an emergency basis outside clinical trials,
provided that: no proven effective treatment exists; it is not possible to initiate clinical studies
immediately; the patient or his or her legal representative has given informed consent for the use
of an experimental medicine with potential side-effects; and the emergency use of the
intervention is monitored, including side-effects; and the results are documented and shared in a
timely manner with the wider medical and scientific community. More details can be found here
https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19
2
WHO is closely monitoring the evidence emerging from global research and regularly updating
the technical guidance on COVID-19 patient management. Member states should use this to
inform the development of national treatment protocols.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-
guidance/patient-management].
WHO Solidarity clinical trial on potential COVID-19 treatment options
The WHO Solidarity trial (SOLIDARITY) currently includes the following drugs: chloroquine or
hydroxychloroquine; lopinavir and ritonavir; lopinavir/ritonavir plus interferon beta; and
remdesivir. The experimental antiviral remdesivir, is not licensed for any indication.
SOLIDARITY is an international randomized trial of in hospitalized patients who are all receiving
the local standard of care. WHO would like to remind that the use of investigational anti-COVID-
19 therapeutics (outside MEURI) should be done under ethically approved, randomized controlled
trials (RCT) only. SOLIDARITY has an adaptive-design and therefore it is anticipated that
additional medications will be added by WHO based on emerging evidence. WHO is facilitating
access to thousands of free treatment courses for the trial through donations from many
manufacturers. The effectiveness of the therapeutics included in the protocol, namely
lopinavir/ritonavir, chloroquine phosphate, hydroxychloroquine, remdesivir, and interferon Beta
1a, must be demonstrated in RCTs before they can be considered for approval in clinical use in
COVID-19 patients.
Remdesivir is not available for general procurement. It is an investigational drug, which can only
be used in the context of phase III clinical trials. There has been some release on case by case basis
for compassionate use by Gilead (producer). Since 23 March 2020, Gilead suspended access to
remdesivir for compassionate use (excepting cases of critically ill children and pregnant women),
for reasons related to supply, citing the need to continue to provide the agent for testing in clinical
trials.
Other authorities, such as the European Medicines Agency (EMA), have issued advice that
chloroquine and hydroxychloroquine are only to be used in clinical trials or emergency use
programmes. Please consult the document at: https://www.ema.europa.eu/en/news/covid-19-
chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes.
WHO is monitoring the impact on supplies to treat malaria and working with suppliers to increase
production.
Non-SOLIDARITY Trial potential treatments
IL6/IL-1 antagonists
An informal consultation on the potential role of IL6/IL-1 antagonists in the clinical management
of COVID-19 infection was hosted in Geneva, Switzerland on 25th March 2020. Given the very
limited evidence of the potential benefits of IL-6 inhibitors, including tocilizumab, the group
agreed further work was required and commissioned a background paper to describe the
rationale and justification for the inclusion of these therapies in an RCT. Therefore, at the
3
moment, there is an inconclusive opinion whether the use of IL6/IL1 antagonists in RCT is
justified. The full report is available following the link https://www.who.int/blueprint/priority-
diseases/key-action/Expert_group_IL6_IL1_call_25_mar2020.pdf?ua=1
Favipiravir
Favipiravir is an investigational drug which is not available for procurement and which can only
be used in the context of phase III clinical trials. The manufacturers have launched a phase III
trial in COVID-19 patients. To date it has only been licensed for influenza when other antiviral
drugs are either not effective or insufficiently effective and animal experiments showed the
potential for teratogenic effects. Its production and distribution are at the discretion of Japan’s
Health, Labor and Welfare Ministry, so has never been distributed in the market and is not
available at hospitals and pharmacies in Japan or overseas.
UNOPS is currently assisting the Ministry of Foreign Affairs of Japan to distribute a donation of
AVIGAN to 27 countries in the WHO European Region, which have requested the drug (Turkey,
Luxembourg, Estonia, Bulgaria, Kosovo, Albania, San Marino, Kazakhstan, Slovenia, Georgia,
Czech Republic, Poland, Hungary, Russia, Azerbaijan, Israel, Uzbekistan, Serbia, additional
countries to be specified). UNOPS will be responsible for logistical facilitation, i.e. bringing the
drug from the manufacturer in Japan to the respective Ministry of Health in the requesting
country. Quantities are relatively small and aim to treat 100 potential patients in each country.
Convalescent Plasma
WHO’s guidance on the use of convalescent plasma states:“experience suggests that empirical
use of convalescent plasma (CP) may be a potentially useful treatment for COVID-19. Detailed
risk assessment must always be conducted to ensure that the blood service has sufficient
capability to safely collect, process and store these specific blood components in a quality-
assured manner” https://apps.who.int/iris/rest/bitstreams/1272656/retrieve
WHO has previously released interim guidance for the use of CP collected from patients
recovered from Ebola Virus Disease. Additionally, the WHO Blood Regulators Network
(https://www.who.int/bloodproducts/brn/en/)
Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an
Element in Response to an Emerging Virus (2017) provides helpful considerations”
https://www.who.int/bloodproducts/brn/2017_BRN_PositionPaper_ConvalescentPlasma.pdf?u
a=1. The International Society of Blood Transfusion website has further COVID-19 specific
resources [http://isbtweb.org/index.php?id=1493]
WHO Research and Development Blueprint
As part of WHO’s response to the outbreak, the WHO Research and Development Blueprint (R&D
Blueprint) has been activated to accelerate research into diagnostics, vaccines, and therapeutics for
this novel coronavirus. R&D Blueprint has been closely following the available evidence and
4
developments in the areas of novel therapeutics, vaccines and other measures for the management
of COVID-19 cases through the involvement of a wide community of leading world scientists. The
current updates on the research and development streams, including for prophylactic or post
exposure prophylactic use can be accessed here
/https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-
novel-coronavirus-2019-ncov https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-
HEO-RDBlueprint%28nCoV%29-2020.1-eng.pdf
Global availability of essential medicines
It is inevitable that shortages of medicines for use in SOLIDARITY as well as in other RCT will
occur before supply chains can adapt to meet global demand as countries are in the process of
procuring the same products.
Moreover, Member States should ensure there are sufficient supplies of essential medicines
needed for use in non-COVID patients with life-threatening conditions such as HIV and malaria,
which are targeted for use in the SOLIDARITY trial as well as in other RCT.
Countries procurement of essential medicines for use in non-COVID-19 patients should be based
on estimates of previous consumption. Stockpiling in large quantities will exacerbate the global
situation.
5
Saatja: BLINKENBERG, Nina Lillian <
[email protected]>
Saadetud: 16.04.2020 15:44
Adressaat: Tanel Kiik <
[email protected]>; Triin Uusberg
<
[email protected]>
Koopia: Elen Ohov <
[email protected]>; Triin Uusberg <
[email protected]>;
SM Info <
[email protected]>; <
[email protected]>; <
[email protected]>;
REINAP, Marge <
[email protected]>
Teema: ESTONIA: WHO Regional Office for Europe: Information on the use
of experimental medicines for the treatment of novel coronavirus disease
(COVID-19) patients
Dear Sir,
On behalf of the Regional Director, please find attached information on
the use of experimental medicines for the treatment of novel coronavirus
disease (COVID-19) patients.
Sincerely,
Health Emergencies Programme
WHO Regional Office for Europe
WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
Date: 16 April 2020
REGIONAL OFFICE FOR EUROPE Mr Tanel Kiik
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA Minister of Social Affairs
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО Ministry of Social Affairs
Head office:
Suur-Ameerika 1
UN City, Marmorvej 51, 10129 Tallinn
DK-2100 Copenhagen Ø, Denmark Estonia
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected]
Website: http://www.euro.who.int
Our reference: Your reference:
Notre référence: Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Sir,
WHO Regional Office for Europe
advice on the use of experimental medicines for the treatment of novel coronavirus disease
(COVID-19) patients
The World Health Organization (WHO) Regional Office for Europe presents its compliments to the
Ministry of Health of Estonia.
WHO is providing support to countries for the clinical management of novel coronavirus disease
(COVID-19) patients, and in that regard has developed evidence-based guidance on clinical
management of severe acute respiratory infection when COVID-19 disease is suspected.1 Optimized
supportive care should be provided to ensure the best possible chance of survival for COVID-19
patients. Management of severe COVID-19 requires oxygen therapy and monitoring, while
management of critical COVID-19 requires advanced oxygen or ventilatory support. WHO is also
supporting the procurement of medical supplies for supportive therapy.
By means of this letter, I would like to inform you about the use of experimental drugs in COVID-19
patients. More details can be found in the enclosed paper.
Since there are currently no known effective or licensed treatment options for COVID-19, WHO has
activated its Research and Development Blueprint to accelerate research into diagnostics, vaccines, and
therapeutics for this novel coronavirus disease. WHO has also launched the global “Solidarity” single
randomized clinical trial for the following four drugs: chloroquine or hydroxychloroquine; lopinavir
and ritonavir; lopinavir/ritonavir plus interferon beta; and remdesivir. Since use of these medicines for
COVID-19 management remains experimental, it is critical that they are used under the safeguards
of national regulations for clinical trials. All of the medicines included in the “Solidarity” trial have
known safety profiles for conditions other than COVID-19. However, dosage and interaction with other
interventions in the context of COVID-19 patients needs to be ascertained. Significant side effects,
particularly when combined with other drugs, cannot be excluded. Robust pharmacovigilance and
adverse event reporting are therefore crucial. WHO teams are at your disposal to discuss the details and
can be contacted at the following address:
[email protected].
1 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
If a randomized controlled trial is not possible, any use of investigational therapeutics should be in line
with the framework of Monitored Emergency Use of Unregistered Interventions (MEURI). WHO has
issued a scientific brief on the off-label use of medicines for COVID-19, which states that it can be
ethically appropriate to offer individual patients experimental interventions on an emergency basis
outside clinical trials, provided that: no proven effective treatment exists; it is not possible to initiate
clinical studies immediately; the patient or his or her legal representative has given informed consent
for the use of an experimental medicine with potential side-effects; the emergency use of the
intervention, including side-effects, is monitored; and the results are documented and shared in a timely
manner with the wider medical and scientific community.2
We would like to bring to the attention of countries that have received donations of favipiravir, that in
the context of COVID-19 it is an investigational drug and should only be used as part of a randomized
controlled trial or under the MEURI framework.
The enclosed paper also provides information on the implications for global supplies of essential
medicines used to treat patients with life-threatening conditions, such as HIV and malaria, where these
medicines are included in clinical trials. Based on estimates of previous consumption, WHO
recommends that countries ensure sufficient stockpiles are available, while also warning against
stockpiling in large quantities so as not to exacerbate global shortages.
WHO is closely monitoring the evidence emerging from global research and regularly updating its
technical guidance on COVID-19 patient management. Member States should use this to inform the
development of national treatment protocols.
In the hope that this information is found useful, WHO stands ready to continue providing technical
assistance and aid to the Government of Estonia and its Ministry of Health in particular.
The WHO Regional Office for Europe avails itself of the opportunity to renew to you the assurances of
its highest consideration and thanks you for our collaboration in the best interests of the health of the
Estonian people, particularly in respect of efforts to protect them against the COVID-19 pandemic.
Yours very truly,
Dr Hans Henri P. Kluge
Regional Director
Encls:
WHO Regional Office for Europe advice on the use of experimental medicines for the treatment of COVID-19 patients.
Copy for information to:
Ms Elen Ohov, Adviser, European Union Affairs and International Co-operation Department, Ministry of
Social Affairs, Suur-Ameerika 1, 10122 Tallinn, Estonia
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs,
Suur-Ameerika 1, 10129 Tallinn, Estonia
H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative,
2 https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19
–2–
Permanent Mission of the Republic of Estonia to the United Nations Office and other international
organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland
H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, agréé, Embassy of the
Republic of Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark
Ms Marge Reinap, Acting Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81,
10617 Tallinn, Estonia
–3–